METTL8 show lower alteration frequency of 3% in Ovarian serous cystadenocarcinoma, 3% in Cholangiocarcinoma, and 2% in Lung squamous cell carcinoma (Fig. 4d). Here, METTL8 is linked to cholangiocarcinoma.